169,700 Shares in Intuitive Surgical, Inc. $ISRG Bought by Alecta Tjanstepension Omsesidigt

Key Points

• Alecta Tjanstepension Omsesidigt has made a significant investment of $92.22 million by acquiring 169,700 shares of Intuitive Surgical, Inc. in the second quarter.
• Intuitive Surgical's stock has an average rating of "Moderate Buy" with a price target of approximately $595.95, reflecting positive outlooks from multiple analysts.
• Insider transactions raised concerns as executives sold a total of 45,224 shares in the last three months, which indicates potential changes in sentiment among company insiders.

Alecta Tjanstepension Omsesidigt purchased a new position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 169,700 shares of the medical equipment provider's stock, valued at approximately $92,217,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in ISRG. Chilton Capital Management LLC raised its stake in shares of Intuitive Surgical by 614.3% during the 1st quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 43 shares in the last quarter. Global Financial Private Client LLC raised its stake in shares of Intuitive Surgical by 253.3% during the 1st quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock worth $26,000 after purchasing an additional 38 shares in the last quarter. Elite Financial Inc. bought a new stake in shares of Intuitive Surgical during the 1st quarter worth approximately $26,000. LFA Lugano Financial Advisors SA bought a new stake in shares of Intuitive Surgical during the 1st quarter worth approximately $30,000. Finally, TD Capital Management LLC raised its stake in shares of Intuitive Surgical by 300.0% during the 1st quarter. TD Capital Management LLC now owns 60 shares of the medical equipment provider's stock worth $30,000 after purchasing an additional 45 shares in the last quarter. Institutional investors own 83.64% of the company's stock.

Intuitive Surgical Trading Up 0.7%

ISRG stock traded up $2.89 during trading hours on Friday, hitting $438.72. 3,756,410 shares of the stock were exchanged, compared to its average volume of 2,285,360. The firm has a market capitalization of $157.27 billion, a P/E ratio of 61.19, a P/E/G ratio of 4.57 and a beta of 1.61. The company has a 50-day simple moving average of $476.64 and a two-hundred day simple moving average of $504.12. Intuitive Surgical, Inc. has a 12 month low of $425.00 and a 12 month high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share for the quarter, topping the consensus estimate of $1.93 by $0.26. The firm had revenue of $2.44 billion for the quarter, compared to analysts' expectations of $2.35 billion. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%.The company's quarterly revenue was up 21.4% compared to the same quarter last year. During the same quarter last year, the business earned $1.78 EPS. On average, equities research analysts predict that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Amy L. Ladd sold 336 shares of the firm's stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $470.11, for a total value of $157,956.96. Following the transaction, the director owned 1,074 shares in the company, valued at approximately $504,898.14. This trade represents a 23.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Myriam Curet sold 4,500 shares of the firm's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $492.48, for a total value of $2,216,160.00. Following the completion of the transaction, the executive vice president owned 353 shares in the company, valued at $173,845.44. The trade was a 92.73% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 45,224 shares of company stock worth $21,716,492 in the last 90 days. Company insiders own 0.70% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ISRG. Wells Fargo & Company upped their price objective on Intuitive Surgical from $559.00 to $599.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 23rd. UBS Group increased their price target on Intuitive Surgical from $547.00 to $585.00 and gave the company a "neutral" rating in a research note on Wednesday, July 23rd. Wall Street Zen upgraded Intuitive Surgical from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Erste Group Bank restated a "hold" rating on shares of Intuitive Surgical in a research note on Wednesday, July 23rd. Finally, BTIG Research increased their price target on Intuitive Surgical from $566.00 to $571.00 and gave the company a "buy" rating in a research note on Wednesday, July 23rd. Thirteen investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $595.95.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.